Aurinia Pharmaceuticals Inc
$ 14.59
-1.62%
24 Feb - close price
- Market Cap 1,955,196,000 USD
- Current Price $ 14.59
- High / Low $ 14.96 / 14.50
- Stock P/E 26.48
- Book Value 2.77
- EPS 0.56
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.21 %
- 52 Week High 16.54
- 52 Week Low 6.55
About
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Analyst Target Price
$16.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-07-31 | 2025-04-30 | 2025-02-13 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-02-28 |
| Reported EPS | 0.23 | 0.16 | 0.16 | 0.01 | 0.1 | 0.01 | -0.03 | -0.19 | -0.09 | -0.08 | -0.18 | -0.18 |
| Estimated EPS | 0.16 | 0.14 | 0.1 | -0.016 | 0.01 | 0.01 | -0.14 | -0.16 | -0.17 | -0.18 | -0.22 | -0.27 |
| Surprise | 0.07 | 0.02 | 0.06 | 0.026 | 0.09 | 0 | 0.11 | -0.03 | 0.08 | 0.1 | 0.04 | 0.09 |
| Surprise Percentage | 43.75% | 14.2857% | 60% | 162.5% | 900% | 0% | 78.5714% | -18.75% | 47.0588% | 55.5556% | 18.1818% | 33.3333% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.21 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AUPH
2026-02-21 12:10:28
Jupiter Asset Management Ltd. decreased its stake in Aurinia Pharmaceuticals by 11.8% in Q3, now holding 823,579 shares valued at $9.10 million. Other institutions like JPMorgan Chase & Co. increased their holdings, bringing total institutional ownership to 36.83%. Analyst sentiment is mixed, with an average "Hold" rating and a price target of $17.25, though some analysts have upgraded the stock.
2026-02-19 11:57:16
Aurinia Pharmaceuticals announced it will report its financial results for the three and twelve months ended December 31, 2025, and provide a business update on February 26, 2026. This update will offer insights into the progress of its flagship lupus nephritis drug LUPKYNIS and investigational autoimmune therapy aritinercept, and their impact on the company's growth trajectory. An analyst from TipRanks' AI Analyst, Spark, rates AUPH as "Outperform," citing strong financial performance and promising clinical developments.
2026-02-19 10:57:16
Aurinia Pharmaceuticals Inc (AUPH) is scheduled to release its financial results for the fourth quarter and full year 2025 on February 26, 2026. The company's management will provide a detailed interpretation of the financial report, discuss recent business developments, and outline strategic progress. This event aims to offer investors and market observers a comprehensive understanding of Aurinia's financial status and operational performance.
2026-02-19 10:57:16
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced it will report its financial results for the three and twelve months ending December 31, 2025, and provide a business update on February 26, 2026. The company's management team will host a webcast and conference call at 8:30 a.m. ET on that date. Aurinia specializes in biopharmaceuticals for autoimmune diseases, including LUPKYNIS® for lupus nephritis and aritinercept in development.
2026-02-18 05:56:00
This article provides a technical analysis of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), highlighting divergent sentiment across different time horizons. It outlines institutional trading strategies based on AI models, including position trading, momentum breakout, and risk hedging strategies, with specific entry, target, and stop-loss zones. The analysis also details support and resistance levels for near-term, mid-term, and long-term outlooks for AUPH.
2026-02-15 09:26:56
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received a consensus "Hold" rating from analysts, with an average one-year price target of $17.25 based on reports from six analysts. While Jefferies upgraded AUPH to a "Buy" with a $21 price target, other firms generally maintained or lowered their ratings. The company's stock is trading near $14.23, with strong liquidity and institutional ownership.
